Dr Martens. Here to stay.
Equity opportunity in misunderstood, growing and transforming brand.
The post-Covid reversal really caught many companies overextended. But many of them did not lose the engines of growth and profitability they had pre-Covid.
This company has a unique brand, a strong balance sheet and is profitable while making moves for a better future.
The valuation is just stupid, and hopefully it will get stupider — giving us the chance to buy this even cheaper!
For those interested in making income while the thesis plays out, this is a dividend payer too.
The moves they are making right now are resulting in higher top line and increased bottom-line margin. The strategy still has room to go.
Without further delay, let’s jump in.
